Dr Reddy's Laboratories launched Anti-allergy Drug, Fexofenadine HCl tablets in US Market

Hyderabad based Pharma major Dr Reddy's Laboratories on 14 April 2011 launched its anti-allergy drug, Fexofenadine HCl tablets, in the US market. Dr Reddy’s received approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Fexofenadine HCl tablets. The US District Court of New Jersey had given a go ahead for the launch of the drug by Dr Reddy's in the US back in January 2011. The US Court also ordered Sanofi-Aventis and Albany Molecular Research, which had earlier obtained an injunction against launching of the drug by Dr Reddy’s to post a security of $ 40 million with the Court towards the likelihood that the injunction had been wrongfully granted.

Dr Reddy's would market the product which is bioequivalent version of Sanofi-Aventis' Allegra tablets under store brand labels in the US market and would be sold over the counter. The Fexofenadine HCl market had brand and generic sales of approximately $452 million for the 12 months ending 31 December 2010.